The patent has been granted
The patent has been granted, Grant of patent is intended, Examination is in progress, Request for examination was made, The application has been published
EP Register Verified
HIGH CONCENTRATION VEGF RECEPTOR FUSION PROTEIN CONTAINING FORMULATIONS
Publication No.
EP4364724
•
App No.
EP24156902
•
Filed by
Regeneron Pharmaceuticals, Inc.
•
Filed on
2019-05-10
•
Issued/Published on
2025-11-26
Publication No.
EP4364724
A2
Application No.
EP24156902
Filed: 2019-05-10
Grant Date
2025-11-26
Mention of grant
Active Oppositions
13 Active
EPO Oppositions
Patent Abstract / Summary
[0001] The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
IPC Classifications
A61K9/00, A61K38/17, A61K47/22, A61P27/02, A61K47/26, A61K9/08
A61K9/08
Priority Claims
US 201862669506P
Date: 2018-05-10
US 201862752127P
Date: 2018-10-29
US 201862769876P
Date: 2018-11-20
US 201962813882P
Date: 2019-03-05
Designated Contracting States (38 EPC States)
AL
AT
BE
BG
CH
CY
CZ
DE
DK
EE
ES
FI
FR
GB
GR
HR
HU
IE
IS
IT
LI
LT
LU
LV
MC
MK
MT
NL
NO
PL
PT
RO
RS
SE
SI
SK
SM
TR
Parties & Representation
Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
USInventors (2)
GRAHAM, Kenneth S.
Pleasant Valley, 12569
USWADHWA, Saurabh
Nanuet, 10954
USRepresentatives / Agents
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB, Arabellastraße 30
DEJ A Kemp LLP
80 Turnmill Street, London EC1M 5QU
GBPotter Clarkson
Chapel Quarter, Mount Street
GBUexküll & Stolberg
Partnerschaft von, Patent- und Rechtsanwälten mbB
DETer Meer und Partner mbB
Nymphenburger Str. 4, Zugang Dachauer Str. 63
DEMaiwald GmbH
Elisenhof, Elisenstraße 3
DEkaro IP
Patentanwälte PartG mbB, Steinstraße 16-18
DEBoult Wade Tennant LLP
Salisbury Square House, 8 Salisbury Square
GBBischof, Oliver
Bischof & Partner, Rechtsanwälte Partnerschaftsgesellschaft mbB
DELeonard, Thomas Charles
Kilburn & Strode LLP, Lacon London
GBPetraz, Davide Luigi, et al
GLP S.r.l, Viale Europa Unita, 171
ITD Young & Co LLP
3 Noble Street, London EC2V 7BQ
GBEIP
Fairfax House, 15 Fulwood Place
GBKey Procedural Dates
Request-For-Examination
2025-02-06
Mention Of Grant Published
2025-11-26
First-Examination-Report-Despatched
2025-04-01
Patent Oppositions
Official opposition proceedings filed against European Patent EP4364724 under EPC Article 99.
#1
Opponent
Company
Advanz Pharma Services (UK) Ltd
UK (Corporate Headquarters), GB
Representative
Potter Clarkson
Filing
Date
Opposition in Progress
2026-08-21
#2
Opponent
Company
Amgen Inc.
One Amgen Center Drive, US
Representative
Uexküll & Stolberg
Filing
Date
Opposition in Progress
2026-08-21
#3
Opponent
Company
Intas Pharmaceuticals Limited
Corporate House, IN
Representative
Ter Meer und Partner mbB
Filing
Date
Opposition in Progress
2026-08-24
#4
Opponent
Company
Sandoz AG
Centralbahnstrasse 4, CH
Representative
Maiwald GmbH
Filing
Date
Opposition in Progress
2026-08-24
#5
Opponent
Company
Neuefeind, Regina
Maiwald GmbH, DE
Representative
Maiwald GmbH
Filing
Date
Opposition in Progress
2026-08-25
#6
Opponent
Company
QILU PHARMACEUTICAL CO., LTD.
No.23999, GongYe Bei Road, CN
Representative
karo IP
Filing
Date
Opposition in Progress
2026-08-25
#7
Opponent
Company
Boult Wade Tennant LLP
Salisbury Square House, GB
Representative
Boult Wade Tennant LLP
Filing
Date
Opposition in Progress
2026-08-25
#8
Opponent
Company
Bischof & Partner Rechtsanwälte Partnerschaftsgesellschaft mbB
An den Speichern 6, DE
Representative
Bischof, Oliver
Filing
Date
Opposition in Progress
2026-08-25
#9
Opponent
Company
Kilburn & Strode LLP
Lacon London, GB
Representative
Leonard, Thomas Charles
Filing
Date
Opposition in Progress
2026-08-25
#10
Opponent
Company
KIVIAL Srl
Viale Europa Unita, 171, IT
Representative
Petraz, Davide Luigi, et al
Filing
Date
Opposition in Progress
2026-08-26
#11
Opponent
Company
karo IP Patentanwälte PartG mbB
Steinstraße 16-18, DE
Representative
—
Filing
Date
Opposition in Progress
2026-08-26
#12
Opponent
Company
Hampton Knowles Limited
3 Noble Street, GB
Representative
D Young & Co LLP
Filing
Date
Opposition in Progress
2026-08-26
#13
Opponent
Company
Alvotech hf.
Saemundargata 15-19, IS
Representative
EIP
Filing
Date
Opposition in Progress
2026-08-26
Legal Status & Event History
Official European Patent Office legal and procedural status changes recorded for this file.
| Date | Code | Event Description | Auth |
|---|---|---|---|
| 2024-04-05 | PUAI | PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE | EP |
| 2024-04-05 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2024-05-08 | AC | DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION | EP |
| 2024-05-08 | AK | DESIGNATED CONTRACTING STATES | EP |
| 2024-07-05 | PUAL | SEARCH REPORT DESPATCHED | EP |
| 2024-08-07 | RIC1 | INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT | EP |
| 2024-08-07 | AK | DESIGNATED CONTRACTING STATES | EP |
| 2024-09-06 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-02-07 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-03-12 | RAX | REQUESTED EXTENSION STATES OF THE EUROPEAN PATENT HAVE CHANGED | EP |
| 2025-03-12 | RAV | REQUESTED VALIDATION STATE OF THE EUROPEAN PATENT: FEE PAID | EP |
| 2025-03-12 | 17P | REQUEST FOR EXAMINATION FILED | EP |
| 2025-03-28 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-04-30 | 17Q | FIRST EXAMINATION REPORT DESPATCHED | EP |
| 2025-07-08 | GRAP | DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT | EP |
| 2025-07-08 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2024-06-28 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-08-06 | INTG | INTENTION TO GRANT ANNOUNCED | EP |
| 2025-10-16 | GRAS | GRANT FEE PAID | EP |
| 2025-10-24 | GRAA | (EXPECTED) GRANT | EP |
| 2025-10-24 | STAA | INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT | EP |
| 2025-11-12 | P01 | OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED | EP |
| 2025-11-26 | AC | DIVISIONAL APPLICATION: REFERENCE TO EARLIER APPLICATION | EP |
| 2025-11-26 | AK | DESIGNATED CONTRACTING STATES | EP |
| 2025-11-26 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-11-27 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-12-11 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-12-22 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-12-17 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-01-05 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2025-12-16 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-01-07 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-01-27 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-02-16 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-02-23 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-02-27 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-03-25 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-04-08 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-05-18 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-04-28 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-06-01 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-05-22 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-06-29 | VS25 | LAPSED IN A VALIDATION STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NAT. OFFICE TO EPO] | EP |
| 2026-07-03 | PG25 | LAPSED IN A CONTRACTING STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-08 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-09 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-10 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-11 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-14 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-14 | VS25 | LAPSED IN A VALIDATION STATE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NAT. OFFICE TO EPO] | EP |
| 2026-07-15 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-16 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-17 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-18 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-21 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-23 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-24 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-25 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-28 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-29 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-07-31 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-08-28 | PLBI | OPPOSITION FILED | EP |
| 2026-08-28 | PLBP | OPPOSITION WITHDRAWN | EP |
| 2026-09-02 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-09-03 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-09-06 | PLAX | NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATION + TIME LIMIT SENT | EP |
| 2026-08-21 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-09-12 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
| 2026-09-18 | PLAF | INFORMATION MODIFIED RELATED TO COMMUNICATION OF A NOTICE OF OPPOSITION AND REQUEST TO FILE OBSERVATIONS + TIME LIMIT | EP |
| 2026-09-15 | REG | REFERENCE TO A NATIONAL CODE | EP |
| 2026-09-30 | 26 | OPPOSITION FILED | EP |
| 2026-10-06 | PGFP | ANNUAL FEE PAID TO NATIONAL OFFICE [ANNOUNCED VIA POSTGRANT INFORMATION FROM NATIONAL OFFICE TO EPO] | EP |
Patent & Non-Patent Citations
Cited documents and prior art referenced in search and examination reports.
Cited Patent Documents
US201962813882
2019-03-05
Espacenet
US201862769876
2018-11-20
Espacenet
US201862752127
2018-10-29
Espacenet
US201862669506
2018-05-10
Espacenet
US7396664
Espacenet
US7354579
Espacenet
WO2005000895
Espacenet
WO2005121176
Espacenet
WO2007112675
Espacenet
US2017232199
Espacenet
WO2019020777
2019-01-31
Espacenet
WO2019055902
2019-03-21
Espacenet
WO2019124946
2019-06-27
Espacenet
WO2007149334
2007-12-27
Espacenet
CA2990582
2016-12-29
Espacenet
WO2017129685
2017-08-03
Espacenet
US2018099049
2018-04-12
Espacenet
US2006217311
2006-09-28
Espacenet
US2016244504
2016-08-25
Espacenet
WO2019108770
2019-06-06
Espacenet
WO2016208989
2016-12-29
Espacenet
WO2017120601
2017-07-13
Espacenet
US2013317457
Espacenet
US2016002341
Espacenet
WO2019217927
Espacenet
US2019031879
Espacenet
WO2016085750
Espacenet
EP2364691
Espacenet
WO2018094316
Espacenet
WO2015173260
Espacenet
WO2017085253
Espacenet
WO2016073915
Espacenet
WO2016073918
Espacenet
WO2012097019
Espacenet
WO2013174936
2013-11-28
Espacenet
WO2017066554
Espacenet
US2010272719
Espacenet
CA3081094
Espacenet
CA2751188
Espacenet
EP3043775
Espacenet
WO2006104852
2006-10-05
Espacenet
WO2015006734
2015-01-15
Espacenet
WO2016045626
2016-03-31
Espacenet
CA2962480
2016-03-31
Espacenet
US2015071920
2015-03-12
Espacenet
US2016144025
Espacenet
US7608261
2009-10-27
Espacenet
US9254338
Espacenet
WO0075319
2000-12-14
Espacenet
US2018298092
2018-10-18
Espacenet
EP2446890
2013-09-18
Espacenet
WO2016065181
2016-04-28
Espacenet
WO2011084750
2011-07-14
Espacenet
US8921316
2016-05-12
Espacenet
US9982032
2018-05-29
Espacenet
US2016058863
2016-03-03
Espacenet
WO2018035470
2018-02-22
Espacenet
WO2009114521
Espacenet
US8945559
Espacenet
Non-Patent Scientific Literature (NPL)
- MAGARI: "Assessing Shelf Life Using Real-Time and Accelerated Stability Tests", BIOPHARM INTL., vol. 16, no. 11, 2003, pages 36 - 48
- GUIDELINES FOR SUBMITTING DOCUMENTATION FOR THE STABILITY OF HUMAN DRUGS AND BIOLOGICS, ROCKVILLE, MD, 1987
- HARDMAN ET AL.: "Goodman and Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL
- WEINERKOTKOSKIE: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS, AND WILKINS
- "Pharmaceutical Dosage Forms: Parenteral Medications", 1993, MARCEL DEKKER
- "Pharmaceutical Dosage Forms: Disperse Systems", 1990, MARCEL DEKKER
- STEVEN SHIRE: "Formulation of proteins and monoclonal antibodies mAbs", 1 January 2015, MONOCLONAL ANTIBODIES: MEETING THE CHALLENGES IN MANUFACTURING, FORMULATION, DELIVERY AND STABILITY OF FINAL DRUG PRODUCT,, PAGE(S) 93 - 120, XP009192951
* the whole document *
* page 107, paragraph "Buffers for pH Control" *
- NEAL WHITAKER ET AL: "A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 106, no. 11, 1 November 2017 (2017-11-01), US, pages 3230 - 3241, XP055449627, ISSN: 0022-3549, DOI: 10.1016/j.xphs.2017.06.017
* page 3235, tables 2-3 *
* page 3240, column left, paragraph 3 *
* page 3234, paragraph last - page 3235, paragraph 1 *
* page 3240, paragraph Conclusions *
- GIANNOS STEVEN A ET AL: "Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 35, no. 4, 28 February 2018 (2018-02-28), pages 1 - 15, XP036466891, ISSN: 0724-8741, [retrieved on 20180228], DOI: 10.1007/S11095-018-2368-7
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION", 1 December 2016 (2016-12-01), XP055565606, Retrieved from the Internet <URL:https://web.archive.org/web/20161206164049if_/https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf> [retrieved on 20190307]
- STEWART MICHAEL W: "Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug", INFLAMMATION & ALLERGY DRUG TAR, BENTHAM SCIENCE PUBLISHERS, NL, vol. 10, no. 6, 1 December 2011 (2011-12-01), pages 497 - 508, XP009172512, ISSN: 1871-5281, DOI: 10.2174/187152811798104872
- ANONYMOUS: "Product information EYLA aflibercept (rch)", 15 April 2015 (2015-04-15), XP093174268, Retrieved from the Internet <URL:https://www.tga.gov.au/sites/default/files/auspar-aflibercept-150721-pi.pdf>
- AVERY ROBERT L., BAKRI SOPHIE J., BLUMENKRANZ MARK S., BRUCKER ALEXANDER J., CUNNINGHAM EMMETT T., D'AMICO DONALD J., DUGEL PRAVIN: "Intravitreal injection technique and monitoring: updated guidelines of an expert panel", RETINA, LIPPINCOTT, WILLIAMS & WILKINS, US, vol. 34, no. Supplement 12, 1 December 2014 (2014-12-01), US , pages S1 - S18, XP009568677, ISSN: 0275-004X, DOI: 10.1097/IAE.0000000000000399
- STRUBLE C., HOWARD S, RELPH J: "S005 Comparison of ocular tissue weights (volumes) and tissue collection techniques in commonly used preclinical animal species", EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH, EVER 2014 ABSTRACT BOOK; OCTOBER 1- 4 2014, EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH, 1 October 2014 (2014-10-01) - 2014-10-04, pages 243, XP093432206
- "Duane's Ophthalmology", 1 January 2006, LIPPINCOTT WILLIAMS & WILKINS, 2006, ISBN: 978-0-7817-5329-6, article ALAN J. RUBY, GEORGE A. WILLIAMS, MARK S. BLUMENKRANZ: "Chapter 11: Vitreous Humor", pages: 1 - 43, XP009568678
- NGUYEN QUAN DONG, CAMPOCHIARO PETER A., SHAH SYED MAHMOOD, BROWNING DAVID J., HUDSON HENRY L., SONKIN PETER L., HARIPRASAD SEENU M: "Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, MARY ANN LIEBERT, INC., NEW YORK, NY., US, vol. 28, no. 6, 1 December 2012 (2012-12-01), US , pages 581 - 588, XP093407928, ISSN: 1080-7683, DOI: 10.1089/jop.2011.0261
- NGUYEN, Q.D. ; SHAH, S.M. ; BROWNING, D.J. ; HUDSON, H. ; SONKIN, P. ; HARIPRASAD, S.M. ; KAISER, P. ; SLAKTER, J.S. ; HALLER, J. : "A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration", OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 116, no. 11, 1 November 2009 (2009-11-01), AMSTERDAM, NL, pages 2141 - 2148.e1, XP026732998, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2009.04.030
- ANONYMOUS: "Eylea 40 mg/ml solution for injection in pre-filled syringe", SUMMARY OF PRODUCT CHARACTERISTICS, EUROPEAN MEDICINES AGENCY (EMA), 26 November 2012 (2012-11-26), pages 1 - 165, XP093432212, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf>
- ANDREA WANG-GILLAM; WILLIAM P. TEW; MACE L. ROTHENBERG; JAKOB DUPONT; WENDY COOPER; LARS STERNAS; GILIANE BUZENET; JEFFREY A. SOSM: "A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 5, 15 October 2011 (2011-10-15), Bo , pages 1958 - 1961, XP035107067, ISSN: 1573-0646, DOI: 10.1007/s10637-011-9753-y
- ANONYMOUS QI SHENG, GABER RAOUF, MESHI AMIT, RAMKUMAR HEMA L., ALAM MOSTAFA, MUFTUOGLU ILKAY KILIC, FREEMAN WILLIAM R.: "HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - PMC", RETINA, LIPPINCOTT, WILLIAMS & WILKINS, US, vol. 38, no. 0, 1 June 2018 (2018-06-01), US , pages 1156 - 1165, XP093432230, ISSN: 0275-004X, DOI: 10.1097/iae.0000000000001726
- D12 - Claim Form, no. HP-2026-000030
- CABRAL THIAGO, MELLO LUIZ GUILHERME M., LIMA LUIZ H., POLIDO JÚLIA, REGATIERI CAIO V., BELFORT RUBENS, MAHAJAN VINIT B.: "Retinal and choroidal angiogenesis: a review of new targets", INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 1 December 2017 (2017-12-01), London, UK , pages 1 - 13, XP093406693, ISSN: 2056-9920, DOI: 10.1186/s40942-017-0084-9
- ANONYMOUS: "Eylea 40 mg/mL solution for injection in pre-filled syringe", ANNEX I - SUMMARY OF PRODUCT CHARACTERISTICS, EUROPEAN MEDICINES AGENCY, 1 September 2020 (2020-09-01), pages 1 - 95, XP093406707
- ANONYMOUS: "Eylea 40 mg/mL solution for injection in pre-filled syringe", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, EUROPEAN MEDICINES AGENCY, 1 January 2026 (2026-01-01), pages 1 - 165, XP093406708
- STEWART MICHAEL W.: "Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration", CLINICAL MEDICINE INSIGHTS: THERAPEUTICS, LIBERTAS ACADEMICA, AUCKLAND, vol. 5, 1 January 2013 (2013-01-01), Auckland , XP093432236, ISSN: 1179-559X, DOI: 10.4137/cmt.s8921
- ANONYMOUS: "Product information EYLA aflibercept (rch)", BAYER AUSTRALIA LTD, 15 April 2015 (2015-04-15), XP093174268, Retrieved from the Internet <URL:https://www.tga.gov.au/sites/default/files/auspar-aflibercept-150721-pi.pdf>
- ANONYMOUS: "PRODUCT INFORMATION EYLEA aflibercept (rch)", PRODUCT INFORMATION, BAYER GROUP, GERMANY, 8 March 2017 (2017-03-08), Germany, pages 1 - 36, XP093432242, Retrieved from the Internet <URL:https://web.archive.org/web/20170308065657/http:/www.bayerresources.com.au/resources/uploads/PI/file10294.pdf>
- CENTER FOR DRUG EVALUATION AND RESEARCH: "Summary Review for Eylea, application number 125387Orig1s000", HTTPS://WWW.ACCESSDATA.FDA.GOV, FDA, US, 18 November 2011 (2011-11-18), US, pages 1 - 29, XP093412347, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000SumR.pdf>
- ANONYMOUS: "Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)", REGENERON, 20 December 2010 (2010-12-20), pages 1 - 4, XP055305305, Retrieved from the Internet <URL:http://newsroom.regeneron.com/common/download/download.cfm?companyid=REGN&fileid=439860&filekey=6174B455-F9B0-4DAD-8A2F-F868C47D180B&filename=537916.pdf>
- D23b - Screenshot of Wayback machine (https://web.archive.org/web/20170308065657/http:/www.bayerresources.com.au/resources/uploads/PI/file10294.pdf)
- WILSON MICHELLE E., SCOTT ADRIENNE W.: "How to Give Intravitreal Injections", EYENET MAGAZINE, AMERICAN ACADEMY OF OPHTHALMOLOGY, 1 April 2013 (2013-04-01), pages 45 - 47, XP093414273
- HO ALLEN C., BUSBEE BRANDON G., REGILLO CARL D., WIELAND MARK R., VAN EVEREN SHERRI A., LI ZHENGRONG, RUBIO ROMAN G., LAI PHILLIP: "Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration", OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 121, no. 11, 1 November 2014 (2014-11-01), AMSTERDAM, NL, pages 2181 - 2192, XP093414144, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2014.05.009
- KHAN MOHAMMED ALI, MASHAYEKHI ARMAN, FERGUSON KYLE, SHIELDS JERRY A., SHIELDS CAROL L.: "High-Dose (2.5 mg) Intravitreal Bevacizumab as Rescue Therapy for Persistent Postradiation Cystoid Macular Edema", OCULAR ONCOLOGY AND PATHOLOGY, S. KARGER AG, vol. 3, no. 3, 1 January 2017 (2017-01-01), pages 168 - 175, XP093432246, ISSN: 2296-4681, DOI: 10.1159/000448719
- WANG JIAMING, LEI CHUNYAN, TAO LIFEI, WU QUAN, KE XIAO, QIU YIGUO, LEI BO: "A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, US, vol. 7, no. 1, 4 April 2017 (2017-04-04), US, pages 1 - 18, XP093414098, ISSN: 2045-2322, DOI: 10.1038/s41598-017-00683-x
- ANONYMOUS: "EYLEA (aflibercept) Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, 1 July 2015 (2015-07-01), XP093370226, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125387s036lbl.pdf>
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION - EYLEA™ (aflibercept) Injection", REGENERON PHARMACEUTICALS, INC., 1 October 2016 (2016-10-01), pages 1 - 8, XP093047258
- JIN SU-EON; HWANG SUNG-JOO: "Ocular delivery systems for the administration of antibody therapeutics", JOURNAL OF PHARMACEUTICAL INVESTIGATION, SPRINGER SINGAPORE, SINGAPORE, vol. 47, no. 5, 31 May 2017 (2017-05-31), Singapore, pages 373 - 382, XP036307221, ISSN: 2093-5552, DOI: 10.1007/s40005-017-0336-6
- GRZYBOWSKI ANDRZEJ, TOLD REINHARD, SACU STEFAN, BANDELLO FRANCESCO, MOISSEIEV ELAD, LOEWENSTEIN ANAT, SCHMIDT ERFURTH URSULA: "2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations", OPHTHALMOLOGICA, KARGER, BASEL, CH, vol. 239, no. 4, 1 May 2018 (2018-05-01), CH , pages 181 - 193, XP009567718, ISSN: 0030-3755, DOI: 10.1159/000486145
- KHURANA RAHUL N.; RAHIMY EHSAN; JOSEPH W. ANTHONY; SAROJ NAMRATA; GIBSON ANDREA; VITTI ROBERT; BERLINER ALYSON J.; CHU KAREN; CHEN: "Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials", AMERICAN JOURNAL OF OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 200, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 161 - 168, XP085646854, ISSN: 0002-9394, DOI: 10.1016/j.ajo.2019.01.005
- ANONYMOUS: "Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD", 11 December 2017 (2017-12-11), pages 1 - 3, XP093407855, Retrieved from the Internet <URL:https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-acceptance-sbla-filing-12-week-dosing>
- ANONYMOUS: "New data for aflibercept show prolonged injection intervals", 12 February 2018 (2018-02-12), pages 1 - 5, XP093407867, Retrieved from the Internet <URL:https://www.bayer.com/media/en-us/new-data-for-aflibercept-show-prolonged-injection-intervals/>
- JEFFREY S. HEIER; DAVID BOYER; QUAN DONG NGUYEN; DENNIS MARCUS; DANIEL B. ROTH; GEORGE YANCOPOULOS; NEIL STAHL; AVNER INGERMAN; RO: "The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing", OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 118, no. 6, 15 March 2011 (2011-03-15), AMSTERDAM, NL, pages 1098 - 1106, XP028372935, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2011.03.020
- STEWART MICHAEL: "Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept", CLINICAL OPHTHALMOLOGY, DOVE MEDICAL PRESS LIMITED, vol. 2012, no. 6, 26 July 2012 (2012-07-26), pages 1175 - 1186, XP093414119, ISSN: 1177-5483, DOI: 10.2147/opth.s33372
- JEFFREY S. HEIER, DAVID M. BROWN, VICTOR CHONG, JEAN-FRANCOIS KOROBELNIK, PETER K. KAISER, QUAN DONG NGUYEN, BERND KIRCHHOF, ALLEN: "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", OPHTHALMOLOGY, ELSEVIER, vol. 119, no. 12, 1 December 2012 (2012-12-01), pages 2537 - 2548, XP055138976, ISSN: 01616420, DOI: 10.1016/j.ophtha.2012.09.006
- ANONYMOUS: "Actemra Prescribing Information", ACTEMRA - REFERENCE ID:3393637, 1 October 2013 (2013-10-01), pages 1 - 40, XP055972203
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION DUPIXENT", FDA - 4075926, 1 March 2017 (2017-03-01), pages 1 - 34, XP093235852
- FDA: "HEMLIBRA ® (emicizumab-kxwh) injection, for subcutaneous use Initial U.S. Approval: 2017", HIGHLIGHTS OF PRESCRIBING INFORMATION, 1 November 2017 (2017-11-01), pages 1 - 16, XP093070084, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf>
* 1-8 *
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION XOLAIR (omalizumab) injection, for subcutaneous use XOLAIR (omalizumab) for injection, for subcutaneous use", HIGHLIGHTS OF PRESCRIBING INFORMATION, FDA, 1 September 2018 (2018-09-01), pages 1 - 34, XP093432296, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103976s5231lbl.pdf>
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION EYLEA HD (aflibercept) injection, for intravitreal use", HIGHLIGHTS OF PRESCRIBING INFORMATION, FDA, 1 October 2024 (2024-10-01), pages 1 - 20, XP093432302, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761355s006lbl.pdf>
- MANDAL ABHIRUP, PAL DHANANJAY; AGRAHARI VIBHUTI; TRINH HOANG MY; JOSEPH MARY; MITRA ASHIM K.: "Ocular delivery of proteins and peptides: Challenges and novel formulation approaches", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 126, 1 February 2018 (2018-02-01), Amsterdam , NL , pages 67 - 95, XP093173129, ISSN: 0169-409X, DOI: 10.1016/j.addr.2018.01.008
- STEVEN J. SHIRE: "Monoclonal Antibodies", 23 April 2015, ELSEVIER , ISBN: 978-0-08-100296-4, article STEVEN J. SHIRE: "7 - Strategies to deal with challenges of developing high-concentration subcutaneous (SC) formulations for monoclonal antibodies (mAbs)", pages: 139 - 152, XP055344539, DOI: 10.1016/B978-0-08-100296-4.00007-5
* page 148 *
- JEZEK JAN, DARTON NICHOLAS J, DERHAM BARRY K, ROYLE NIKKI, SIMPSON IAIN: "Biopharmaceutical formulations for pre-filled delivery devices", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, GB, vol. 10, no. 6, 1 June 2013 (2013-06-01), GB , pages 811 - 828, XP093432310, ISSN: 1742-5247, DOI: 10.1517/17425247.2013.780023
- NEAL WHITAKER, XIONG JIAN, PACE SAMANTHA E., KUMAR VINEET, MIDDAUGH C. RUSSELL, JOSHI SANGEETA B., VOLKIN DAVID B.: "Accepted Manuscript: A Formulation Development Approach to Identify and Select Stable Ultra–High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities", JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER INC, WASHINGTON, vol. 106, no. 11, 1 November 2017 (2017-11-01), Washington, pages 3230 - 3241, XP055449627, ISSN: 0022-3549, DOI: 10.1016/j.xphs.2017.06.017
- HONG TAEHUN, IWASHITA KAZUKI, SHIRAKI KENTARO: "Viscosity Control of Protein Solution by Small Solutes: A Review", CURRENT PROTEIN AND PEPTIDE SCIENCE, BENTHAM SCIENCE PULBISHERS, NL, vol. 19, no. 8, 13 June 2018 (2018-06-13), NL , pages 746 - 758, XP055980092, ISSN: 1389-2037, DOI: 10.2174/1389203719666171213114919
- PENN, J.S. ; MADAN, A. ; CALDWELL, R.B. ; BARTOLI, M. ; CALDWELL, R.W. ; HARTNETT, M.E.: "Vascular endothelial growth factor in eye disease", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 27, no. 4, 1 July 2008 (2008-07-01), GB , pages 331 - 371, XP023611412, ISSN: 1350-9462, DOI: 10.1016/j.preteyeres.2008.05.001
- SINGH RISHI P, KAISER PETER K: "Role of ranibizumab in management of macular degeneration", INDIAN JOURNAL OF OPHTHALMOLOGY, ALL-INDIA OPHTHALMOLOGICAL SOCIETY, BOMBAY, IN, vol. 55, no. 6, 1 November 2007 (2007-11-01), IN , pages 421 - 425, XP093412444, ISSN: 0301-4738, DOI: 10.4103/0301-4738.36475
- MUKHERJI S.K.: "Bevacizumab (Avastin)", AMERICAN JOURNAL OF NEURORADIOLOGY, AMERICAN SOCIETY OF NEURORADIOLOGY, US, vol. 31, no. 2, 1 February 2010 (2010-02-01), US , pages 235 - 236, XP093412446, ISSN: 0195-6108, DOI: 10.3174/ajnr.a1987
- NICHOLAS PAPADOPOULOS; JOEL MARTIN; QIN RUAN; ASHIQUE RAFIQUE; MICHAEL P. ROSCONI; ERGANG SHI; ERICA A. PYLES; GEORGE D. YANCOPOUL: "Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab", ANGIOGENESIS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 15, no. 2, 3 February 2012 (2012-02-03), Do , pages 171 - 185, XP035048394, ISSN: 1573-7209, DOI: 10.1007/s10456-011-9249-6
- JAMES A. DIXON, OLIVER S; OLSON J L; MANDAVA N: "VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration", EXPERT OPINION ON INVESTIGATIONAL DRUGS, INFORMA HEALTHCARE, UK, vol. 18, no. 10, 1 October 2009 (2009-10-01), UK , pages 1573 - 1580, XP055952523, ISSN: 1354-3784, DOI: 10.1517/13543780903201684
- RAMA D JAGER, LLOYD PAUL AIELLO, SAMIR C PATEL, EMMETT T CUNNINGHAM JR: "Risks of intravitreous injection: a comprehensive review", RETINA, vol. 24, no. 5, October 2004 (2004-10-01), pages 676 - 698, XP009568692, ISSN: 0275-004X, DOI: 10.1097/00006982-200410000-00002
- TIAN JIAO, LIU JIA, LIU XIAO, XIAO YANGYAN, TANG LUOSHENG: "Intravitreal infusion: A novel approach for intraocular drug delivery", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, US, vol. 6, no. 1, 25 November 2016 (2016-11-25), US, pages 1 - 6, XP093413901, ISSN: 2045-2322, DOI: 10.1038/srep37676
- DHEERAJ S. TOMAR, SANDEEP KUMAR, SATISH K. SINGH, SUMIT GOSWAMI, LI LI: "Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development", MABS, LANDES BIOSCIENCE, US, vol. 8, no. 2, 17 February 2016 (2016-02-17), US , pages 216 - 228, XP055472488, ISSN: 1942-0862, DOI: 10.1080/19420862.2015.1128606
- SOBOLEWSKA BIANKA, HEIDUSCHKA PETER, BARTZ-SCHMIDT KARL-ULRICH, ZIEMSSEN FOCKE: "pH of anti-VEGF agents in the human vitreous: low impact of very different formulations", INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 1, 1 December 2017 (2017-12-01), London, UK , XP093432998, ISSN: 2056-9920, DOI: 10.1186/s40942-017-0075-x
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION EYLEA HD (aflibercept) injection, for intravitreal use", HIGHLIGHTS OF PRESCRIBING INFORMATION, REGENERON PHARMACEUTICALS, INC., 1 April 2026 (2026-04-01), pages 1 - 7, XP093433007, Retrieved from the Internet <URL:https://www.regeneron.com/downloads/eyleahd_fpi.PDF>
- NICHOLAS W. WARNE;: "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 78, no. 2, 3 March 2011 (2011-03-03), NL , pages 208 - 212, XP028203394, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2011.03.004
- ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION - EYLEA™ (aflibercept) Injection", REGENERON PHARMACEUTICALS, INC., 1 November 2011 (2011-11-01), pages 1 - 15, XP055895379
- WYKOFF CHARLES C, CLARK W LLOYD, NIELSEN JARED S, BRILL JOEL V, GREENE LAURENCE S, HEGGEN CHERILYN L: "Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration", JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, AMCP, ALEXANDRIA, VA., USA, vol. 24, no. 2-a, 1 February 2018 (2018-02-01), Alexandria, Va., USA, pages S3 - S15, XP093414252, ISSN: 1944-706X, DOI: 10.18553/jmcp.2018.24.2-a.s3
- F SEMERARO, F MORESCALCHI, S DUSE, F PARMEGGIANI, E GAMBICORTI, C COSTAGLIOLA: "Aflibercept in wet AMD: specific role and optimal use", DRUG DESIGN, DEVELOPMENT AND THERAPY, DOVE MEDICAL PRESS LTD., UNITED KINGDOM, vol. 7, 5 August 2013 (2013-08-05), United Kingdom , pages 711 - 722, XP055971638, ISSN: 1177-8881, DOI: 10.2147/DDDT.S40215
- ANONYMOUS: "SUMMARY OF PRODUCT CHARACTERISTICS Lucentis 10 mg/ml solution for injection", SUMMARY OF PRODUCT CHARACTERISTICS, EUROPEAN MEDICINES AGENCY, 11 November 2016 (2016-11-11), pages 1 - 97, XP093414299, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/lucentis-epar-product-information_en.pdf>
- MORADI AHMADREZA: "Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema", WORLD JOURNAL OF DIABETES, BAISHIDENG PUBLISHING GROUP INC., vol. 4, no. 6, 1 January 2013 (2013-01-01), pages 303, XP093309849, ISSN: 1948-9358, DOI: 10.4239/wjd.v4.i6.303
- DE OLIVEIRA DIAS JOÃO RAFAEL, DE ANDRADE GABRIEL COSTA, NOVAIS EDUARDO AMORIM, FARAH MICHEL EID, RODRIGUES EDUARDO BÜCHELE: "Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept", INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. 1, 1 December 2016 (2016-12-01), London, UK , pages 3, XP055927160, ISSN: 2056-9920, DOI: 10.1186/s40942-016-0026-y
- D87 - PP’s submission dated 6 February 2025
- BAYER AUSTRALIA LIMITED: "Australian Public Assessment Report for Afibercept", AUSTRALIAN PUBLIC ASSESSMENT REPORT, THERAPEUTIC GOODS ADMINISTRATION (TGA); AUSTRALIAN GOVERNMENT DEPARTMENT OF HEALTH AND AGEING, 30 July 2012 (2012-07-30), pages 1 - 112, XP093433028, Retrieved from the Internet <URL:https://www.tga.gov.au/sites/default/files/auspar-aflibercept-120730.pdf>
- D90a - Sequence alignment comparing the sequence represented by SEQ ID NO: 4 of D90 with the sequence represented by SEQ ID NO: 2 of the opposed patent
- ANONYMOUS: "Assessment report Eylea aflibercept Procedure No.: EMEA/H/C/002392/ (EMA/646256/2012 corr)", ASSESSMENT REPORT, EUROPEAN MEDICINES AGENCY, 20 September 2012 (2012-09-20), pages 1 - 83, XP093433053, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/assessment-report/eylea-epar-public-assessment-report_en.pdf>
- ANONYMOUS: "Definition of intraocular", NCI DICTIONARY OF CANCER, NATIONAL CANCER INSTITUTE, 8 September 2026 (2026-09-08), pages 1 - 2, XP093433060, Retrieved from the Internet <URL:https://www.cancer.gov/publications/dictionaries/cancer-terms/def/intraocular>
- STEWART MICHAEL W: "Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug.", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ PUBLISHING GROUP LTD, BMA HOUSE, TAVISTOCK SQUARE, LONDON, WC1H 9JR, vol. 96, no. 9, 1 September 2012 (2012-09-01), BMA House, Tavistock Square, London, WC1H 9JR, pages 1157 - 1158, XP002729476, ISSN: 0007-1161, DOI: 10.1136/bjophthalmol-2011-300654
- BRANDEN A SALINAS, HASIGE A SATHISH, STEVEN M BISHOP, NICK HARN, JOHN F CARPENTER, THEODORE W RANDOLPH: "Understanding and Modulating Opalescence and Viscosity in a Monoclonal Antibody Formulation", JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER INC, WASHINGTON, vol. 99, 1 January 2010 (2010-01-01), Washington, pages 82 - 93, XP007911793, ISSN: 0022-3549, DOI: 10.1002/jps.21797
- ANONYMOUS: "Viscosity of Newtonian and Non-Newtonian Fluids", RHEOSENSE ARTICLE, RHEOSENSE, INC., 8 September 2026 (2026-09-08), pages 1 - 6, XP093433068, Retrieved from the Internet <URL:https://www.rheosense.com/applications/viscosity/newtonian-non-newtonian>
- STEWART MICHAEL W: "Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS, NL, vol. 10, no. 6, 1 December 2011 (2011-12-01), NL , pages 497 - 508, XP009172512, ISSN: 1871-5281, DOI: 10.2174/187152811798104872
- HARTMAN RACHEL R., KOMPELLA UDAY B.: "Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, MARY ANN LIEBERT, INC., NEW YORK, NY., US, vol. 34, no. 1-2, 1 March 2018 (2018-03-01), US , pages 141 - 153, XP093433096, ISSN: 1080-7683, DOI: 10.1089/jop.2017.0121
- ANONYMOUS: "Guidelines for Intravitreal Injections Procedure 2009", PUBLISHED GUIDELINES, THE ROYAL COLLEGE OF OPHTHALMOLOGISTS, 29 July 2009 (2009-07-29), pages 1 - 6, XP093433112, Retrieved from the Internet <URL:https://web.archive.org/web/20090731213114/http://www.rcophth.ac.uk/docs/scientific/IVTRevisionfinal2009.pdf>
- YORSTON DAVID: "Intravitreal injection technique", COMMUNITY EYE HEALTH JOURNAL, UK, vol. 27, no. 87, 1 January 2014 (2014-01-01), UK , pages 47, XP093433120, ISSN: 0953-6833
- D111 - Expert Report of Professor Hovhannes John Gukasyan 7 April 2025
- D112 - Expert Report of Professor Laurent Kodjikian 7 April 2025
- TIM J. KAMERZELL; REZA ESFANDIARY; SANGEETA B. JOSHI; C. RUSSELL MIDDAUGH; DAVID B. VOLKIN;: "Protein excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 63, no. 13, 26 July 2011 (2011-07-26), Amsterdam , NL , pages 1118 - 1159, XP028320148, ISSN: 0169-409X, DOI: 10.1016/j.addr.2011.07.006
- BEI CHEN, RAQUEL BAUTISTA, KWOK YU, GERARDO A. ZAPATA, MICHAEL G. MULKERRIN, STEVEN M. CHAMOW : "Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.", PHARMACEUTICAL RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 20, no. 12, 1 December 2003 (2003-12-01), Berlin/Heidelberg, pages 1952 - 1960, XP002417746, ISSN: 0724-8741, DOI: 10.1023/B:PHAM.0000008042.15988.c0
- BRIAND. CONNOLLY; CHRIS PETRY; SANDEEP YADAV; BARTHLEMY DEMEULE; NATALIE CIACCIO; JAMIEM.R. MOORE; STEVENJ. SHIRE; YATINR. GOKARN;: "Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter", BIOPHYSICAL JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 103, no. 1, 24 April 2012 (2012-04-24), AMSTERDAM, NL, pages 69 - 78, XP028398737, ISSN: 0006-3495, DOI: 10.1016/j.bpj.2012.04.047
- BINABAJI ELAHEH; MA JUNFEN; ZYDNEY ANDREW L: "Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions", PHARMACEUTICAL RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 32, no. 9, 2 April 2015 (2015-04-02), Berlin/Heidelberg, pages 3102 - 3109, XP035525930, ISSN: 0724-8741, DOI: 10.1007/s11095-015-1690-6
- DEAR BARTON J.; HUNG JESSICA J.; TRUSKETT THOMAS M.; JOHNSTON KEITH P.: "Contrasting the Influence of Cationic Amino Acids on the Viscosity and Stability of a Highly Concentrated Monoclonal Antibody", PHARMACEUTICAL RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 34, no. 1, 11 November 2016 (2016-11-11), Berlin/Heidelberg, pages 193 - 207, XP036119687, ISSN: 0724-8741, DOI: 10.1007/s11095-016-2055-5
- CAO JINGTAI, MACPHERSON THOMAS C., IGLESIAS BIBIANA V., LIU YANG, TIRKO NATASHA, YANCOPOULOS GEORGE D., WIEGAND STANLEY J., ROMANO: "Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 59, no. 2, 15 February 2018 (2018-02-15), US , pages 1033 - 1044, XP093414102, ISSN: 1552-5783, DOI: 10.1167/iovs.17-22897
- M. GRAZIA SPIGA; BRIAN C GILGER; DAVID CULP: "Chronic Model of Retinal Neovascularization (RNV) in New Zealand Red Rabbits. IOVS ARVO Journals", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE - IOVS, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY - ARVO, vol. 60, no. 9, 1 July 2019 (2019-07-01) - 2019-05-02, pages 2568, XP093433173, ISSN: 0146-0404
- D121a - B. Gilger: "Chronic model of retinal neovascularization (RNV) in New Zealand red rabbits" Association for Research in Vision and Ophthalmology Annual Meeting. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Vancouver, BC 2019 conference paper
- DE OLIVEIRA DIAS JOÃO RAFAEL, BADARÓ EMMERSON, NOVAIS EDUARDO AMORIM, COLICCHIO DANIEL, CHIARANTIN GABRIELLY, MATIOLI MARIANA MAUR: "Preclinical Investigations of Intravitreal Ziv-Aflibercept", OPHTHALMIC SURGERY, LASERS AND IMAGING RETINA, SLACK, THOROFARE, NJ, vol. 45, no. 6, 1 November 2014 (2014-11-01), Thorofare, NJ, pages 577 - 584, XP009568739, ISSN: 2325-8160, DOI: 10.3928/23258160-20141118-15
- REGENERON PHARMACEUTICALS, INC.: "NCT04126317 Clinical Study Protocol A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION", CLINICAL STUDY PROTOCOL, 9 August 2019 (2019-08-09), pages 1 - 109, XP093433854, Retrieved from the Internet <URL:https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2807967> DOI: 10.1001/jamaophthalmol.2023.2421
- AHMAD M. MANSOUR: "Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept", CORNEA, MASSON PUB. USA, UNITED STATES, vol. 36, no. 8, 1 August 2017 (2017-08-01), United States, pages 1002 - 1005, XP009567786, ISSN: 0277-3740, DOI: 10.1097/ICO.0000000000001251
- ANONYMOUS: " EYLEA® (aflibercept) Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, 1 May 2017 (2017-05-01), XP093164525, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125387s054lbl.pdf>
- RAAFAY SOPHIE, ABEER AKHTAR, YASIR J. SEPAH, MOHAMED IBRAHIM,
MILLENA BITTENCOURT, DIANA V. DO, QUAN DONG NGUYEN: "Aflibercept: A Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases", BIOLOGICS IN THERAPY, SPRINGER HEALTHCARE COMMUNICATIONS LTD., GB, vol. 2, no. 1, 1 January 2012 (2012-01-01), GB , pages 1 - 22, XP002734685, ISSN: 2195-5840, DOI: 10.1007/s13554-012-0003-4
- OELLERS PATRICK, GREWAL DILRAJ, FEKRAT SHARON: "Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials", CLINICAL OPHTHALMOLOGY, DOVE MEDICAL PRESS LIMITED, vol. 10, 8 March 2016 (2016-03-08), pages 411 - 418, XP093433856, ISSN: 1177-5483, DOI: 10.2147/opth.s98853
- FERRARA NAPOLEONE, ANTHONY P. ADAMIS: "Ten years of anti-vascular endothelial growth factor therapy", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 15, no. 6, 1 June 2016 (2016-06-01), GB , pages 385 - 403, XP093433859, ISSN: 1474-1776, DOI: 10.1038/nrd.2015
- DO D V; NGUYEN Q D; SHAH S M; BROWNING D J; HALLER J A; CHU K; YANG K; CEDARBAUM J M; VITTI R L; INGERMAN A; CAMPOCHIARO P A: "An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ PUBLISHING GROUP, UK, vol. 93, no. 2, 1 February 2009 (2009-02-01), UK , pages 144 - 149, XP009158490, ISSN: 1468-2079, DOI: 10.1136/bjo.2008.138271
- K. BAILEY FREUND, CHANDRAKUMAR BALARATNASINGAM, ELONA DHRAMI-GAVAZI, JESSE MCCANN, QURAISH GHADIALI: "Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration", CLINICAL OPHTHALMOLOGY, DOVE MEDICAL PRESS LTD., NZ, vol. 9, NZ , pages 2355 - 2371, XP055359313, ISSN: 1177-5467, DOI: 10.2147/OPTH.S80040
- SHUJING WANG, NING ZHANG, TAO HU, WEIGUO DAI, XIUYING FENG, XINYI ZHANG, FENG QIAN: "Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies", MOLECULAR PHARMACEUTICS, AMERICAN CHEMICAL SOCIETY (ACS), vol. 12, no. 12, 7 December 2015 (2015-12-07), pages 4478 - 4487, XP055385371, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.5b00643
- DUGEL PRAVIN U.; JAFFE GLENN J.; SALLSTIG PETER; WARBURTON JAMES; WEICHSELBERGER ANDREAS; WIELAND MARK; SINGERMAN LAWRENCE: "Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial", OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 124, no. 9, 24 May 2017 (2017-05-24), AMSTERDAM, NL, pages 1296 - 1304, XP085180107, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2017.03.057
- CLEAR-AMD 1 STUDY GROUP ; NGUYEN, Q.D. ; SHAH, S.M. ; HAFIZ, G. ; QUINLAN, E. ; SUNG, J. ; CHU, K. ; CEDARBAUM, J.M. ; CAMPOCHIARO: "A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration", OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 113, no. 9, 1 September 2006 (2006-09-01), AMSTERDAM, NL, pages 1522.e1 - 1522.e14, XP027899618, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2006.05.055
- D136 - Declaration of Stephen Brocchini, PhD
* 181-193 *
- SATOSHI OHTAKE, YOSHIKO KITA AND TSUTOMU ARAKAWA: "Interactions of formulation excipients with proteins in solution and in the dried state", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, 1 January 2011 (2011-01-01), Amsterdam , NL , pages 1 - 21, XP055484746, ISSN: 0169-409X, DOI: 10.1016/j.addr.2011.06.011
- WILLIAM F. WEISS, TERESA WEISS, CHRISTOPHER YOUNG, ROBERTS: "Principles, approaches, and challenges for predicting protein aggregation rates and shelf life", JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER INC, WASHINGTON, vol. 98, no. 4, 1 April 2009 (2009-04-01), Washington, pages 1246 - 1277, XP055085272, ISSN: 0022-3549, DOI: 10.1002/jps.21521
- WANG WEI, ROBERTS CHRISTOPHER J.: "Non-Arrhenius Protein Aggregation", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, vol. 15, no. 3, 1 July 2013 (2013-07-01), US , pages 840 - 851, XP093433865, ISSN: 1550-7416, DOI: 10.1208/s12248-013-9485-3
- "Methods for Stability Testing of Pharmaceuticals", 1 May 2018, SPRINGER NEW YORK, New York, NY, ISBN: 978-1-4939-7685-0, article CHAN CHRISTINE P.: "Chapter 15: Stability Testing Considerations for Biologicals and Biotechnology Products", pages: 335 - 347, XP009568742, DOI: 10.1007/978-1-4939-7686-7_15
* page 338 *
Worldwide Patent Family
Related applications and patents in the same INPADOC worldwide family.
| Country | Publication Number | Kind | Publication Date | Action |
|---|---|---|---|---|
| EP | EP4364724A2 | A2 | 2024-05-08 | Espacenet |
| EP | EP4364724A3 | A3 | 2024-08-07 | Espacenet |
| EP | EP4364724B1 | B1 | 2025-11-26 | Espacenet |
| AU | AU2019265005A1 | A1 | 2020-12-17 | Espacenet |
| AU | AU2019265005B2 | B2 | 2025-03-13 | Espacenet |
| AU | AU2024100037A4 | A4 | 2024-10-24 | Espacenet |
| AU | AU2024100037B4 | B4 | 2025-04-10 | Espacenet |
| AU | AU2025204229A1 | A1 | 2025-06-26 | Espacenet |
| AU | AU2025204229B2 | B2 | 2026-09-17 | Espacenet |
| BR | BR112020022610A2 | A2 | 2021-02-09 | Espacenet |
| CA | CA3099551A1 | A1 | 2019-11-14 | Espacenet |
| CA | CA3099551C | C | 2025-08-19 | Espacenet |
| CA | CA3281979A1 | A1 | 2026-03-02 | Espacenet |
| CL | CL2020002872A1 | A1 | 2021-03-26 | Espacenet |
| CL | CL2021001957A1 | A1 | 2022-04-08 | Espacenet |
| CL | CL2023003448A1 | A1 | 2024-07-19 | Espacenet |
| CN | CN112739323A | A | 2021-04-30 | Espacenet |
| CN | CN112739323B | B | 2025-11-25 | Espacenet |
| CN | CN116585466A | A | 2023-08-15 | Espacenet |
| CN | CN118948760A | A | 2024-11-15 | Espacenet |
| CN | CN121421956A | A | 2026-01-30 | Espacenet |
| CN | CN121570417A | A | 2026-02-27 | Espacenet |
| CO | CO2020014427A2 | A2 | 2020-12-21 | Espacenet |
| DK | DK4364724T3 | T3 | 2025-12-22 | Espacenet |
| EA | EA202092700A1 | A1 | 2021-02-02 | Espacenet |
| EP | EP3790532A1 | A1 | 2021-03-17 | Espacenet |
| EP | EP3790532B1 | B1 | 2026-09-02 | Espacenet |
| EP | EP4684776A2 | A2 | 2026-01-28 | Espacenet |
| EP | EP4684776A3 | A3 | 2026-04-22 | Espacenet |
| EP | EP4813373A2 | A2 | 2026-09-30 | Espacenet |
| ES | ES3056525T3 | T3 | 2026-02-23 | Espacenet |
| FI | FI4364724T3 | T3 | 2026-01-05 | Espacenet |
| HR | HRP20260001T1 | T1 | 2026-02-27 | Espacenet |
| IL | IL278375A | A | 2020-12-31 | Espacenet |
| IL | IL278375B1 | B1 | 2025-03-01 | Espacenet |
| IL | IL278375B2 | B2 | 2025-07-01 | Espacenet |
| IL | IL318714A | A | 2025-03-01 | Espacenet |
| JO | JOP20200275A1 | A1 | 2020-11-02 | Espacenet |
| JP | JP2021523162A | A | 2021-09-02 | Espacenet |
| JP | JP7235770B2 | B2 | 2023-03-08 | Espacenet |
| JP | JP2023071798A | A | 2023-05-23 | Espacenet |
| JP | JP7791125B2 | B2 | 2025-12-23 | Espacenet |
| JP | JP2026058347A | A | 2026-04-03 | Espacenet |
| KR | KR20210021299A | A | 2021-02-25 | Espacenet |
| KR | KR20260141137A | A | 2026-09-28 | Espacenet |
| LT | LT4364724T | T | 2026-01-12 | Espacenet |
| MA | MA52570A | A | 2021-03-17 | Espacenet |
| MX | MX2020011848A | A | 2021-03-29 | Espacenet |
| MX | MX421310B | B | 2025-03-14 | Espacenet |
| MX | MX2024014765A | A | 2025-01-09 | Espacenet |
| MX | MX2025001448A | A | 2025-03-07 | Espacenet |
| MY | MY204232A | A | 2024-08-16 | Espacenet |
| NZ | NZ770284A | A | 2025-11-28 | Espacenet |
| PH | PH12020551839A1 | A1 | 2021-06-28 | Espacenet |
| PL | PL4364724T3 | T3 | 2026-02-23 | Espacenet |
| PT | PT4364724T | T | 2025-12-16 | Espacenet |
| RS | RS67656B1 | B1 | 2026-02-27 | Espacenet |
| SG | SG11202010684YA | A | 2020-11-27 | Espacenet |
| SI | SI4364724T1 | T1 | 2026-01-30 | Espacenet |
| US | US2019343918A1 | A1 | 2019-11-14 | Espacenet |
| US | US11103552B2 | B2 | 2021-08-31 | Espacenet |
| US | US2021353714A1 | A1 | 2021-11-18 | Espacenet |
| US | US12168036B2 | B2 | 2024-12-17 | Espacenet |
| US | US20240058418A1 | A1 | 2024-02-22 | Espacenet |
| US | US20250121030A1 | A1 | 2025-04-17 | Espacenet |
| WO | WO2019217927A1 | A1 | 2019-11-14 | Espacenet |
Official File Inspection
EPC Art. 128 Public Dossier
Complete European Patent Register Dossier (148 Total Documents)
The full inspection file for Application EP24156902 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.
Recorded Filings & Patent Specifications
Official publication specifications, opposition filings, proprietor replies, and procedural submissions.
European Patent Specification - Granted Patent (B1)
Publication Specification
Date: 2025-11-26
Procedure: Grant
EP4364724B1
Official European Patent Register Full Dossier
Publication Specification
Date: 2025-11-26
Procedure: All Proceedings (Examination & Opposition)
EP24156902
European Search Report (A3)
Publication Specification
Date: 2024-08-07
Procedure: Publication
EP4364724A3
European Patent Application without Search Report (A2)
Publication Specification
Date: 2024-05-08
Procedure: Publication
EP4364724A2
Change: Communication of a notice of opposition and request to file observations + time limit
Dossier Filing
Date: 2026-09-18
Procedure: Opposition
EPIDOSCOBS2
Change - representative
Dossier Filing
Date: 2026-09-08
Procedure: Examination
EPIDOS FREP
Invitation to proprietor to file observations on the notice of opposition
Procedural Step
Date: 2026-09-07
Procedure: Opposition
OBSO
New entry: Communication of a notice of opposition and request to file observations + time limit
Dossier Filing
Date: 2026-09-06
Procedure: Opposition
EPIDOSNOBS2
Opposition filed
Dossier Filing
Date: 2026-08-28
Procedure: Opposition
0009260
Opposition withdrawn
Dossier Filing
Date: 2026-08-28
Procedure: Opposition
0009264
Lapse of the patent in a contracting state
Dossier Filing
Date: 2026-07-31
Procedure: Examination
0009250
(Expected) grant
Dossier Filing
Date: 2025-10-24
Procedure: Grant
0009210
New entry: Receipt of the translation of the claim(s)
Dossier Filing
Date: 2025-10-17
Procedure: Examination
EPIDOSNIGR7
New entry: Payment of fee for grant
Dossier Filing
Date: 2025-10-16
Procedure: Grant
EPIDOSNIGR3
New entry: Payment of fee for publishing/printing
Dossier Filing
Date: 2025-10-16
Procedure: Examination
EPIDOSNIGR5
New entry: Communication of intention to grant a patent
Dossier Filing
Date: 2025-07-08
Procedure: Grant
EPIDOSNIGR1
Intention to grant the patent
Procedural Step
Date: 2025-07-08
Procedure: Grant
IGRA
New entry: Renewal fee paid
Dossier Filing
Date: 2025-05-21
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2025-05-20
Procedure: Examination
RFEE
New entry: Reply to examination report
Dossier Filing
Date: 2025-04-25
Procedure: Examination
EPIDOSNEXR3
New entry: Despatch of examination report + time limit
Dossier Filing
Date: 2025-04-02
Procedure: Examination
EPIDOSNEXR2
Communication from the examining division
Procedural Step
Date: 2025-04-01
Procedure: Examination
EXRE
First examination report
Dossier Filing
Date: 2025-03-28
Procedure: Examination
0009185
Amendment by applicant
Dossier Filing
Date: 2025-02-08
Procedure: Examination
EPIDOS ABEX
New entry: Fee payment for extension state
Dossier Filing
Date: 2025-02-07
Procedure: Examination
EPIDOSNEXP2
New entry: Fee payment for validation state
Dossier Filing
Date: 2025-02-07
Procedure: Examination
EPIDOSNVAP2
The date on which the examining division becomes responsible, has been established
Dossier Filing
Date: 2025-02-07
Procedure: Examination
EPIDOSNEXAM52
Request for examination filed
Dossier Filing
Date: 2025-02-07
Procedure: Examination
0009171
Change - extension states
Dossier Filing
Date: 2025-02-07
Procedure: Examination
0009199EXPT
Change: Validation states
Dossier Filing
Date: 2025-02-07
Procedure: Examination
0009199VAPT
Validation of the patent
Procedural Step
Date: 2025-02-06
Procedure: Examination
VAPT
Date on which the examining division has become responsible
Procedural Step
Date: 2025-02-06
Procedure: Examination
EXAM52
Amendments
Procedural Step
Date: 2025-02-06
Procedure: Examination
ABEX
Extension of the patent
Procedural Step
Date: 2025-02-06
Procedure: Examination
EXPT
Change - classification
Dossier Filing
Date: 2024-07-05
Procedure: Examination
0008199IPCL
Publication of search report
Dossier Filing
Date: 2024-07-05
Procedure: Examination
0009013
Publication in section I.1 EP Bulletin
Dossier Filing
Date: 2024-04-05
Procedure: Examination
0009012
Change - representative
Dossier Filing
Date: 2024-02-09
Procedure: Examination
EPIDOS FREP
New entry: Renewal fee paid
Dossier Filing
Date: 2024-02-09
Procedure: Examination
EPIDOSNRFE2
Renewal fee payment
Procedural Step
Date: 2024-02-09
Procedure: Examination
RFEE
Language of the procedure
Procedural Step
Procedure: Examination
PROL
International searching authority
Procedural Step
Procedure: Examination
ISAT